Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

Esteban Martínez; Juan A. Arnaiz; Daniel Podzamczer; David Dalmau; Esteban Ribera; Pere Domingo; Hernando Knobel; Maria Leyes; Enric Pedrol; Luís Force; Elisa De Lazzari; José M. Gatell

doi:10.1097/QAD.0b013e3280121ab1

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

Esteban Martínez^*, Juan A. Arnaiz, Daniel Podzamczer, David Dalmau, Esteban Ribera, Pere Domingo, Hernando Knobel, Maria Leyes, Enric Pedrol, Luís Force, Elisa De Lazzari, José M. Gatell

^*Corresponding author for this work

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

35 Citations (Scopus)

Abstract

Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.

Original language	American English
Pages (from-to)	367-369
Number of pages	3
Journal	AIDS
Volume	21
Issue number	3
DOIs	https://doi.org/10.1097/QAD.0b013e3280121ab1
Publication status	Published - Jan 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0b013e3280121ab1

Cite this

@article{8865a11724a54ff195f743b90e963a89,

title = "Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients",

abstract = "Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.",

author = "Esteban Mart{\'i}nez and Arnaiz, {Juan A.} and Daniel Podzamczer and David Dalmau and Esteban Ribera and Pere Domingo and Hernando Knobel and Maria Leyes and Enric Pedrol and Lu{\'i}s Force and {De Lazzari}, Elisa and Gatell, {Jos{\'e} M.}",

year = "2007",

month = jan,

doi = "10.1097/QAD.0b013e3280121ab1",

language = "Ingl{\'e}s estadounidense",

volume = "21",

pages = "367--369",

number = "3",

}

TY - JOUR

T1 - Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

AU - Martínez, Esteban

AU - Arnaiz, Juan A.

AU - Podzamczer, Daniel

AU - Dalmau, David

AU - Ribera, Esteban

AU - Domingo, Pere

AU - Knobel, Hernando

AU - Leyes, Maria

AU - Pedrol, Enric

AU - Force, Luís

AU - De Lazzari, Elisa

AU - Gatell, José M.

PY - 2007/1

Y1 - 2007/1

N2 - Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.

AB - Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.

UR - http://www.scopus.com/inward/record.url?scp=33846587991&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3280121ab1

DO - 10.1097/QAD.0b013e3280121ab1

M3 - Artículo

C2 - 17255745

AN - SCOPUS:33846587991

SN - 0269-9370

VL - 21

SP - 367

EP - 369

JO - AIDS

JF - AIDS

IS - 3

ER -

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this